ClinicalTrials.gg
RecruitingNCT07853131Updated Oct 23, 2026

Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function

A Phase 1 interventional study of rilzabrutinib in Renal Impairment and Healthy Volunteers, sponsored by Sanofi. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 23, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Renal Insufficiency by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Renal Insufficiency · Sanofi.

Planned enrollment
10th of 12
16 · median 45
Started
2026
the only one that year
Phase 1
6 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Renal Insufficiency by Sanofi, this one is the 10th largest by planned enrollment, is the only one that started in 2026, is one of 6 in phase 1, and was the 12th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

1 of the 12 studies in Renal Insufficiency by Sanofi is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Renal Insufficiency by Sanofi, or all of them as a file.
02

Study summary

The purpose of this Phase 1, open-label, 2-arm study is to assess the effect of severe RI on PK, safety, and tolerability of rilzabrutinib compared with normal renal function, in male and female participants aged from 18 to 75 years.

The total duration of the study per participant will be approximately 30 days, including:

  • A screening period of up to 27 days.
  • A 3-day, open-label treatment period, with a single dose on Day 1.
  • A 1-day follow-up period (Day 3) with an allowable 2-day window (ie, Day 3 to Day 5).
03

Conditions studied

  • Renal Impairment
  • Healthy Volunteers

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • If participants with severe renal impairment: Stable severe chronic kidney disease (no dialysis) assessed by medical history, physical examination, laboratory values.
  • If participants with normal renal function: Certified as healthy by a comprehensive clinical assessment.
  • Body weight between 50.0 and 115.0 kg, inclusive, if male, and between 40.0 and 100.0 kg, inclusive, if female, and between 18.0 and 40.0 kg/m2, inclusive, at screening.
  • use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Regular intake of nicotine more than 10 mg per day and unable to stop smoking during the study (occasional smoker can be enrolled).
  • History or presence of drug or alcohol abuse.
  • If participants with severe renal impairment:

    • Uncontrolled cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness, unless the Investigator considers an abnormality to be not .
    • Participants with a history of serious infection requiring intravenous therapy within 4 weeks of study enrollment.
    • Any significant change in chronic treatment medication within 14 days before inclusion.
  • If participants with normal renal function

    • Any history or presence of clinically relevant hepatic or renal disease.
    • For participants 50 years of age and younger: Any history or presence of cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness, unless the Investigator considers an abnormality to be not clinically significant.
    • For participants above 50 years of age: Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female) or infectious disease, or signs of acute illness, unless the Investigator considers an abnormality to be not clinically significant.
    • Frequent headaches and/or migraine, recurrent nausea and/or vomiting. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Participants with severe renal impairment

    Treated with single dose of rilzabrutinib

    Drug: rilzabrutinib

  • Experimental
    Participants with normal renal function

    Treated with single dose of rilzabrutinib

    Drug: rilzabrutinib

Interventions

  • Pharmaceutical form: Tablet Route of administration: Oral

    Also known as: SAR444671

06

What researchers measure

Primary outcomes

  1. Rilzabrutinib: AUC

    area under the plasma concentration versus time curve

    Time frame: Until Day 2

Secondary outcomes

  1. Rilzabrutinib: Cmax

    Time frame: Until Day 2

  2. Rilzabrutinib: unbound Cmax

    Time frame: Until Day 2

  3. Rilzabrutinib: AUClast

    Time frame: Until Day 2

  4. Rilzabrutinib: unbound AUC

    Time frame: Until Day 2

  5. Rilzabrutinib: CL/F

    Time frame: Until Day 2

  6. Rilzabrutinib: t1/2z

    Time frame: Until Day 2

  7. Adverse events (AEs)

    incl. Clinical laboratory evaluations, Vital signs, Electrocardiogram (ECG)

    Time frame: Until Day 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Apr 2027, 6 months after the start.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 6 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Oct 1, 2026
StartActual
Sep 22, 2026was Oct 2026
Primary completionEst.
Apr 21, 2027
CompletionEst.
Apr 21, 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 23, 2026
Sites
1 site added — first site in United States
Show site
  • Clinical Pharmacology of Miami- Site Number : 8400001 · Hialeah, United States
Oct 23, 2026
Start date
Oct 9, 2026→Sep 22, 2026 (actual)
Oct 23, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Oct 23, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Clinical Pharmacology of Miami- Site Number : 8400001 · Hialeah, United States
    Start date Oct 9, 2026→Sep 22, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853131
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Sep 22, 2026
Primary completion
Apr 21, 2027 (estimated)
Completion
Apr 21, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilzabrutinib

Start the discussion